RESUMO
This study sought the characterization of rotaviruses in a trial with a tetravalent rhesus-human rotavirus vaccine in Belém, Brazil in children who received three doses of vaccine or placebo in the 1st, 3rd and 5th months of life. Rotavirus electropherotypes, subgroups, G serotypes, G, [P] and [P],G genotypes were determined in 93.3 percent, 95.9 percent, 93.3 percent, 73.3 percent, 95.5 percent and 92.2 percent of isolates, respectively. Serotypes G1, G2 and G4 were detected in 58.9 percent, 30 percent and 4.4 percent of the cases, respectively. Rotavirus genotype G5 was detected for the first time in Northern region in 4.4 percent of the infections. Rotavirus genotypes P[8], P[4], P[6] and P[8+6] were detected in 54.5 percent, 26.7 percent, 12.2 percent, and 2.2 percent of the cases, respectively. The predominant genotypes were P[8],G1 and P[4],G2 with 53 percent and 26.6 percent of the infections, respectively. Unusual strains accounted for 20.5 percent including P[4],G1, P[6],G1, P[6],G4, P[6],G5, P[8],G2, P[8],G5. Mixed infections involving P[8+6],G2 and P[8+6],G1 were also noted. The neonatal P[6] strains associated with diarrhea were detected among children aged 9-24 months. To our knowledge, this study represents the first in Brazil to analyse, on molecular basis, rotavirus genotypes from children participating in a rotavirus vaccine trial. These results are of potential importance regarding future rotavirus vaccination strategies in Brazil
Assuntos
Humanos , Lactente , Pré-Escolar , Criança , Variação Genética , Rotavirus , Vacinas contra Rotavirus , Brasil , Método Duplo-Cego , Gastroenterite , Genótipo , Estudos Prospectivos , Rotavirus , SorotipagemRESUMO
Infeccoes simultaneas por sorotipos 1 e 4 de rotavirus foram observadas em uma crianca de 15 meses de idade, do sexo feminino, internada com diarreia aguda contraida na comunidade que perdurou por 7 dias, evoluindo com desidratacao moderada. As evidencias dessas infeccoes foram inferidas baseadas em testes tais como: a) ensaio imunoenzimatico (ELISA), evidenciando-se reacao positiva para os sorotipos 1 e 4; e b) migracoes extras de segmentos de ARN visualizados a eletroforese em gel de poliacrilamida (EGPA). Esses resultados sugerem que as condicoes precarias de higiene e saneamento em que vivia essa crianca propiciam a infeccao macica por esses agentes virais. Alem disso, a co-circulacao de diferentes sorotipos no mesmo ambiente sustenta a necessidade de utilizar-se, no futuro, uma vacina polivalente, que proteja as criancas contra os quatro sorotipos G, epidemiologicamente importantes
Assuntos
Humanos , Feminino , Lactente , Diarreia/etiologia , Infecções por Rotavirus/patologia , Rotavirus/classificação , Sintomas Concomitantes , Desidratação/complicações , Infecções por Rotavirus/transmissão , Sorotipagem/classificaçãoRESUMO
Se evaluó la inocuidad, inmunogenicidad y eficacia de una vacuna tetravalente obtenida por recombinación genética de rotavirus aislados de monos rhesus y seres humanos (RRV-TV) (4 x 104 unidades formadoras de placas por dosis) en un ensayo prospectivo, aleatorio, a doble ciego y controlado con placebo que se efectuó con 540 lactantes brasileños. Se administraron dosis de vacuna o de placebo a la edad de 1, 3 y 5 meses. No se observaron diferencias significativas en la frecuencia de diarrea o vómito en los bebés de ninguno de los dos grupos después de administrar la dosis correspondiente. De 2 a 3% de los vacunados tuvieron fiebre baja los días tercero a quinto después de recibir la primera dosis, pero no después de las dosis segunda o tercera. Se observó una respuesta de anticuerpos del tipo IgA al rotavirus aislado de monos rhesus (RRV) en 58% de los vacunados y en 33% de quienes recibieron placebo. La respuesta de anticuerpos neutralizantes a cada serotipo no pasó de 20% cuando se determinó con la prueba de reducción de focos de fluorescencia, pero fue superior a 40% al medirse con la prueba de neutralización a base de reducción de placas. Se presentaron 91 casos de diarrea causada por rotavirus entre los niños que recibieron las tres dosis (de vacuna o de placebo) durante un seguimiento de 2 años, 36 de ellos en los niños vacunados. La eficacia general de la vacuna fue de 8% (P = 0,005) contra toda clase de diarrea y de 35% (P = 0,03) contra la diarrea causada por rotavirus. La protección durante el primer año de seguimiento, cuando predominó el rotavirus G del serotipo 1, fue de 57% (P = 0,008), pero se redujo a 12% en el segundo año. Se obtuvieron resultados similares al restringir el análisis a episodios en que el rotavirus fue el único agente patógeno identificado. Se observó en la vacuna una mayor tendencia a proteger contra casos de enfermedad con un promedio de seis o más deposiciones diarias. Estos resultados son lo suficientemente...
A tetravalent rhesus-human reassortant rotavirus (RRV-TV) vaccine (4 x 104 plaque-forming units/dose) was evaluated for safety, immunogenicity and efficacy in a prospective, randomized, double-blind, placebo-controlled trial involving 540 Brazilian infants. Doses of vaccine or placebo were given at ages, 1, 3 and 5 months. No significant differences were noted in the occurrence of diarrhoea or vomiting in vaccine and placebo recipients following each dose. Low-grade fever occurred on days 35 in 23% of vaccinees after the first dose, but not after the second or third doses of vaccine. An IgA antibody response to rhesus rotavirus (RRV) occurred in 58% of vaccinees and 33% of placebo recipients. Neutralizing antibody responses to individual serotypes did not exceed 20% when measured by fluorescent focus reduction, but exceeded 40% when assayed by plaque reduction neutralization. There were 91 cases of rotavirus diarrhoea among the 3-dose (vaccine or placebo) recipients during two years of follow-up, 36 of them among children given the vaccine. Overall vaccine efficacy was 8% (P = 0.005) against any diarrhoea and 35% (P = 0.03) against any rotavirus diarrhoea. Protection during the first year of follow-up, when G serotype 1 rotavirus predominated, was 57% (P = 0.008), but fell to 12% in the second year. Similar results were obtained when analysis was restricted to episodes in which rotavirus was the only identified pathogen. There was a tendency for enhanced protection by vaccine against illness associated with an average of 6 or more stools per day. These results are sufficiently encouraging to warrant further studies of this vaccine in developing countries using a higher dosage in an attempt to improve its immunogenicity and efficacy.